RxDoctor Payments DataLook up a doctor →

Marla Morgan, MD

Neurology · Birmingham, ALNPI 1003848821

Payments from drug & device makers

$46,265in general payments, 2019–2025

Across 930 payments — averaging $49.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$30K
  • AbbVie$2K
  • Biogen$1K
  • UCB, Inc.$993
  • Neurocrine Biosciences, Inc.$846
  • Novartis$774
  • plus $10K from 53 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)89$30,250
AbbVie(2 entities)115$1,885
Biogen61$1,136
UCB, Inc.47$993
Neurocrine Biosciences, Inc.34$846
Novartis44$774
Neurelis, Inc.34$657
Pfizer36$640
Amgen(2 entities)30$606
SK Life Science, Inc.26$517
Lilly USA, LLC31$506
Supernus Pharmaceuticals, Inc.23$504
Eisai Inc.28$497
TG Therapeutics, Inc.14$436
Avanir Pharmaceuticals, Inc.21$344
Genentech USA, Inc.19$330
Adamas Pharmaceuticals, Inc.18$301
Bristol Myers Squibb18$301
Teva Pharmaceuticals USA, Inc.21$296
Lundbeck LLC14$292
Livanova USA, Inc.6$282
CSL Behring13$268
Biohaven Pharmaceutical Holding Company Ltd.17$267
EMD Serono, Inc.12$248
Sanofi12$241
Argenx US, Inc.9$239
Sumitomo Pharma America, Inc.12$212
Sunovion Pharmaceuticals Inc.11$203
Johnson & Johnson(2 entities)8$196
Catalyst Pharmaceuticals, Inc.8$188
Greenwich Biosciences, Inc.9$173
Grifols USA, LLC7$167
MDD US Operations, LLC9$163
Otsuka America Pharmaceutical, Inc.14$150
Scilex Pharmaceuticals Inc.6$121
Corium, LLC6$121
Upsher-smith Laboratories LLC7$119
ANI Pharmaceuticals, Inc.5$103
E.r. Squibb & Sons, L.L.C.2$93
Kyowa Kirin, Inc.4$79
Portola Pharmaceuticals, LLC4$66
Takeda Pharmaceuticals U.S.A., Inc.3$43
Almatica Pharma LLC2$41
Acadia Pharmaceuticals Inc2$40
Jazz Pharmaceuticals Inc.2$37
Tanabe Pharma America, Inc.2$32
Impel Pharmaceuticals Inc.2$32
Amneal Pharmaceuticals LLC2$29
Medtronic1$26
Dynasplint Systems Inc.1$26
Octapharma USA, Inc.1$22
Immedica Pharma US, Inc.1$21
Mallinckrodt Hospital Products Inc.1$20
Ceribell, Inc.1$18
Azurity Pharmaceuticals, Inc.1$17
Arbor Pharmaceuticals, Inc.1$14
Genentech, Inc.1$13
Avion Pharmaceuticals1$12
Assertio Therapeutics, Inc.1$12

How this compares

$46,265 in reported general payments places this provider in the 75th percentile of 255 neurology providers in Alabama.

See all neurology providers in Alabama →

Medicare billing

Part B allowed, 2024
$98,212
Medicare patients
289
Services billed
8,481

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Birmingham

See the full list for Alabama →

Where these figures come from

Is this you, or does something look wrong? →